Drug intelligence / Profile preview

alloClae

Development stage: Unknown
Lead developer: Tiger Aesthetics Medical
Modality: Cell Therapies
Administration: Subcutaneous

Overview

alloClae is a structural adipose tissue-based allograft developed by Tiger Aesthetics Medical (a division of Tiger Biosciences) for aesthetic body contouring. It is composed of terminally sterilized, intact adipocytes and extracellular matrix (ECM) that retain their natural 3D honeycomb structure to provide immediate volume, cushioning, and support. Unlike traditional fat grafting, alloClae is a "ready-to-use" donor-derived product that does not contain viable cells, eliminating the need for a donor site harvest from the patient. It is intended for subcutaneous application in localized areas where adipose tissue naturally exists to improve body contours.

Brand names: alloClae
Other names: alloClae™

Beyond the preview

Go deeper on alloClae.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alloClae.

Explore the full profile